Cardinal Health (NYSE:CAH) +  shares ticked up today on third-quarter results that beat the consensus forecast.

Shares of CAH rose 1.5% at $82.06 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell 0.5%.

The Dublin, Ohio–based company posted profits of $345 million in the quarter. That amounts to $1.34 per share on sales of $50.5 billion for the three months ended March 31, 2023.

Cardinal Health recorded a massive bottom-line gain from losses of nearly $1.4 billion this time last year. The company posted sales growth of 12.7%. Pharmaceutical sales represented the main growth driver there, rising by 14% year over year. That offset dips in the medical segment, as sales fell by 5% there. Profits in the medical segment slid 66%.

Adjusted to exclude one-time items, earnings per share totaled $1.74. That landed 25¢ ahead of projections on Wall Street. Cardinal Health also beat sales estimates, as analysts expected $49.7 billion in revenue.

“Our third-quarter results were led by continued momentum and growth in the Pharmaceutical segment,” said Jason Hollar, CEO of Cardinal Health. “With the strong overall performance in the quarter, we are pleased to raise our full-year non-GAAP EPS guidance by $0.35 at the midpoint. In Medical, we continue to see improvement in underlying performance and remain confident in our Medical Improvement Plan initiatives.

“Across the enterprise, we continue to operate with urgency to drive our businesses forward and create value for our shareholders.”

Cardinal Health raised its adjusted EPS guidance for between $5.60 and $5.80. It previously projected a range of $5.20 to $5.50. The company is less optimistic about a rebound in its Medical segment, lowering its profit expectations to about a 50% decline. It previously expected flat growth to a decline of 20%.